The full results of the ANNEXA-I trial have continued to show mixed effects of the factor Xa inhibitor reversal agent, andexanet (Andexxa/Ondexxya, AstraZeneca), in patients with intracerebral ...
Please provide your email address to receive an email when new articles are posted on . AIMS65 score predicted mortality and rebleeding for patients on anticoagulants with gastrointestinal bleeding.
The phase 4 ANNEXA-I trial was stopped early after showing superior hemostatic efficacy and the capability to limit potentially life-threatening intracerebral hemorrhage (ICH) compared with usual care ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback